Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2019
Assuntos:
Theranostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://ncbi.nlm.nih.gov/pubmed/30291194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados